Pereira, SACaixas, UBranco, TGermano, ILampreia, FPapoila, ALMonteiro, E2014-04-082014-04-082008Br J Clin Pharmacol. 2008 Oct;66(4):551-5http://hdl.handle.net/10400.17/1776AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.engCHLC MEDDoenças HepáticasInibidores de Transcriptase ReversaProjectos PilotoÍndice de Gravidade da DoençaResultado de TratamentoCarga ViralInfecções Oportunistas Relacionadas com a SIDABenzoxazinasContagem de Linfócito CD4Estudos de Casos e ControlesEvolução da DoençaRelação Dose-Resposta a MedicamentoMonitorização de MedicamentosEstudos de Follow-UpInfecção por HIVHepatite B CrónicaHepatite C CrónicaMetabolismojournal article